Wu, X., et al., “Raloxifene increases hippocampal choline acetyltransferase activity in ovariectomized rats.” Society For Neuroscience Abstracts, vol. 24, No. 1-2, pp. 732, 1998 (XP002111355). |
Nickelsen, T, et al., “Raloxifene hydrochloride, a selective estrogen receptor modulator: safety assessment of effects on cognitive function and mood in postmenopausal women” Psychoneuroendocrinology (1998) 24(1), 115-128, 1999 (XP002111819). |
Fuchs-Young, R. et al., “Preclinical demonstration of specific and potent inhibition of mammary tumor growth by new selective estrogen receptor modulators (SERMS)” Proceedings of the American Association For Cancer Research Annual Meeting (1997) vol. 38 No. 0, PP 573 (XP002111820). |
Mohs, et al., “Oral Physostigmine Treatment of Patients with Alzheimer's Disease” American Journal of Psychiatry, vol., 142, 1985 (XP002080514). |
Aquado, F. et al., “Synthesis and Evaluation of Tacrine-Related Compounds for the Treatment of Alzheimer's Disease” European Journal of Medicinal Chemistry Chimica Therapeutica, vol. 29, 1994 (XP000616050). |
Xin Wu, et al, “Brain Research” Raloxifene and estradiol benzoate both fully restore hippocampal choline acetyltransferase activity in ovariectomized rats, 847, (1999). |
Kirkland, et al., “Tamoxifene Stimulates Expression of the c-fos Proto-Oncogene in Rodent Uterus”, Molecular Pharm vol. 43 709-714, 1993. |
Jordan, et al., “Tamoxifen-stimulated Growth of Human Endometrial Carcinoma” New York Academy of sciences (Publication date not available). |
Malfetano “Tamoxifen-Associated Endometrial Carcinoma in Postmenopausal Breast Cancer Patients”, Academic Press, 1990. |
“Women on Estrogen Appear at Less Risk of Alzheimer's”, Indianapolis, Star, Nov. 10, 1993. |